Royal Bank of Canada (RY)
NYSE: RY · Real-Time Price · USD
130.73
+0.81 (0.62%)
Aug 5, 2025, 4:00 PM - Market closed
Achilles Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Achilles Therapeutics stock has a target of 193, which predicts a 47.63% increase from the current stock price of 130.73.
Price Target: $193.00 (+47.63%)
Analyst Consensus: Buy
* Price targets were last updated on Dec 5, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Achilles Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Maintains $195 → $193 | Buy | Maintains | $195 → $193 | +47.63% | Dec 5, 2024 |
| BMO Capital | BMO Capital | Buy Maintains $151 → $165 | Buy | Maintains | $151 → $165 | +26.21% | Aug 29, 2024 |
| Argus Research | Argus Research | Strong Buy Maintains $115 → $120 | Strong Buy | Maintains | $115 → $120 | -8.21% | Jun 6, 2024 |
| BMO Capital | BMO Capital | Hold → Buy Upgrades $140 → $150 | Hold → Buy | Upgrades | $140 → $150 | +14.74% | Apr 5, 2024 |
| Credit Suisse | Credit Suisse | Buy Maintains $138 → $139 | Buy | Maintains | $138 → $139 | +6.33% | Aug 25, 2023 |
Financial Forecast
Revenue This Year
65.97B
from 54.11B
Increased by 21.91%
Revenue Next Year
67.80B
from 65.97B
Increased by 2.78%
EPS This Year
13.85
from 11.25
Increased by 23.08%
EPS Next Year
14.84
from 13.85
Increased by 7.17%
Financial currency is CAD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 68.2B | 70.6B | 73.8B |
| Avg | 66.0B | 67.8B | 70.1B |
| Low | 59.3B | 60.4B | 63.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 26.0% | 7.0% | 8.9% |
| Avg | 21.9% | 2.8% | 3.5% |
| Low | 9.5% | -8.4% | -6.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 14.70 | 15.89 | 16.79 |
| Avg | 13.85 | 14.84 | 16.05 |
| Low | 12.46 | 13.72 | 14.75 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 30.7% | 14.7% | 13.1% |
| Avg | 23.1% | 7.2% | 8.1% |
| Low | 10.7% | -0.9% | -0.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.